BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 35CR
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP487056
下载链接
链接失效反馈官方服务：
资源简介：
To study the effect of inhibiting AR and HNF1A/HNF4G activity either alone or in combination on the growth of CRPC PDX LuCaP 35CR Overall design: LuCaP 35CR tumors were treated with enzalutamide, pelabresib or a combination of pelabresib and enzalutamide and tumor volumes were compared to vehicle control
创建时间：
2025-08-21
